RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0

Gelijkaardige items

• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  door: Nishino, Mizuki, et al.
  Gepubliceerd in: (2012)
• Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression
  door: Nishino, Mizuki, et al.
  Gepubliceerd in: (2013)
• Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor
  door: Nishino, Mizuki, et al.
  Gepubliceerd in: (2013)
• RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Targeted Therapy
  door: Krajewski, Katherine M., et al.
  Gepubliceerd in: (2015)
• New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
  door: Nishino, Mizuki, et al.
  Gepubliceerd in: (2010)